KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 6037 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Pharmacological Treatment of Cerebellar Ataxia in Pediatric Ataxia-Telangiectasia: A Systematic Review. PMID 42387837 · Eur J Neurol · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Cross-Platform Gene Signature to Predict Survival Outcomes for Nasopharyngeal Carcinoma. PMID 42385107 · JCO Precis Oncol · 2026-Jul 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Assessing Polypoidal Choroidal Vasculopathy-Related OCT Features in the TENAYA and LUCERNE Trials. PMID 42383222 · Ophthalmol Sci · 2026-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials. PMID 42380713 · BioDrugs · 2026-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Model-Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer. PMID 42337921 · Clin Transl Sci · 2026-Jul The record describes a Phase I PK study with PopPK modeling and simulations to support Phase 3 dose selection. While it is a randomized, drug-intervention oncology study, it reports only pharmacokinetic outcomes (bioavailability, exposure), not time-to-event efficacy endpoints like OS or PFS with Kaplan-Meier or HR. Therefore, it does not meet the core requirement for a time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trials. PMID 42318595 · World Allergy Organ J · 2026-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Off-Protocol Radiotherapy in Prospective Systemic Therapy Trials for Metastatic Non-Small Cell Lung Cancer. PMID 42314501 · Clin Lung Cancer · 2026-Jul The record is a methodological review/meta-analysis of systemic therapy trial protocols, not an original report of trial results. It does not present any primary or secondary time-to-event efficacy data (e.g., OS, PFS, Kaplan-Meier curves, HR) from a randomized trial.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
β-Blockers after myocardial infarction with preserved or mildly reduced left ventricular ejection fraction: Fragility of contemporary evidence. PMID 42306649 · Am Heart J Plus · 2026-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
SOHO State of the Art Updates and Next Questions | Early Stage Hodgkin Lymphoma-Are We Ready for Novel Agents? PMID 42242960 · Clin Lymphoma Myeloma Leuk · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Response to Letter to the Editor: "Efficacy and Safety of Combination Therapy With Low Dose of Telmisartan and S-Amlodipine in Patients With Hypertension: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial". PMID 42215366 · Clin Ther · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Sparsentan Versus Irbesartan in Pediatric Patients With FSGS. PMID 42210914 · Kidney Int Rep · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Trial protocol: RadTARGET, a multicenter phase II randomized controlled trial evaluating focal radiotherapy boost with de-intensification of dose to non-suspicious prostate in patients with intermediate- or high-risk prostate cancer. PMID 42205730 · Clin Transl Radiat Oncol · 2026-Jul 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Complementary evaluation of phase III immunotherapy trials in advanced HCC using the survival-inferred fragility index. PMID 42203603 · Dig Liver Dis · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy translation between phase II and phase III trials in gynecologic oncology: a cross-phase meta-comparative analysis. PMID 42202504 · Int J Gynecol Cancer · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Study outcome and journal impact factor: a meta-epidemiologic analysis of phase III gynecologic oncology trials. PMID 42172953 · Int J Gynecol Cancer · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo. PMID 42171987 · Dermatol Ther (Heidelb) · 2026-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Fosfomycin versus ciprofloxacin for febrile neutropenia prophylaxis in high-risk haematological patients (FOVOCIP): a phase 3, open-label, multicentre, randomised, non-inferiority trial. PMID 42164340 · Lancet Reg Health Eur · 2026-Jul 未发现恶性肿瘤人群证据。
H B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial. PMID 42143645 · Dermatol Ther (Heidelb) · 2026-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Response to the letter to the editor by Pontoriero et al. regarding the article "Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer - PORTEC-4a an international randomised phase 3 trial by Van den Heerik et al.". PMID 42128303 · Radiother Oncol · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial. PMID 42115051 · Ann Rheum Dis · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Rilzabrutinib for persistent or chronic immune thrombocytopenia (ITP): a Bruton tyrosine kinase inhibitor that can target multiple pathophysiological pathways. PMID 42106923 · Expert Rev Hematol · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effects of Guselkumab on Structural Damage Progression in Patients with Active Psoriatic Arthritis. PMID 42084657 · Adv Ther · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Comment on "Efficacy and Safety of Combination Therapy With Low Dose of Telmisartan and S-Amlodipine in Patients With Hypertension: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial". PMID 42070935 · Clin Ther · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Letter to the Editor Regarding "Efficacy and Safety of Combination Therapy With Low Dose of Telmisartan and S-Amlodipine in Patients With Hypertension: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial". PMID 42070934 · Clin Ther · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efgartigimod in Sjögren's disease: a phase 2, randomised, placebo-controlled, parallel-group, double-blinded, proof-of-concept study (RHO). PMID 41997805 · Ann Rheum Dis · 2026-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Evaluating quality of life in thoracic malignancy trials: A scoping review on ESMO-MCBS quality of life checklist adherence and concordance with progression-free and overall survival. PMID 41937091 · Crit Rev Oncol Hematol · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Re: Hiroshi Kitamura, Taiji Tsukamoto, Yoshiyuki Kakehi, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. 2026;89:437-445. PMID 41864760 · Eur Urol · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Safety, tolerability, and immunogenicity of a 31-valent pneumococcal conjugate vaccine (VAX-31) in healthy adults aged 50 years and older from the USA: a phase 1/2, double-blinded, active-controlled, parallel-group, dose-finding randomised clinical trial. PMID 41864214 · Lancet Infect Dis · 2026-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care. PMID 41819988 · Eur J Haematol · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Physical rehabilitation for older patients with acute HFpEF (REHAB-HFpEF) trial: Design and rationale. PMID 41812966 · Am Heart J · 2026-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. PMID 41748387 · Eur Urol · 2026-Jul Eligibility cannot be determined because the record lacks explicit time-to-event endpoint signals and sufficient information about the original formal results and human subject status. Set is_eligible to null.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Adjuvant PD-1 Inhibitors After Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma: A Systematic Review and Meta-Analysis of Phase 3 Trials. PMID 41665515 · Urol Pract · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Identifying clinical correlates of drinking clusters during treatment for alcohol use disorder. PMID 41601244 · Am J Addict · 2026-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The Ethics of Clinical Research on Diseases of the Fetus and Newborn: Balancing Benefit-Risk, Autonomy, and Maternal-Fetal Interests. PMID 41468898 · Am J Perinatol · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Plain Language Summary of Publication: Design of the Phase 3 FREESIA-1 and FREESIA-3 Trials of Nipocalimab in Fetal and Neonatal Alloimmune Thrombocytopenia. PMID 41461173 · Am J Perinatol · 2026-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Fitusiran: A Novel Antithrombin-Targeting Therapy for Hemophilia A and B, With or Without Inhibitors. PMID 41450180 · Ann Pharmacother · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Denifanstat for moderate-to-severe acne: A Phase 2, randomized, double-blind, placebo-controlled trial. PMID 41186280 · J Eur Acad Dermatol Venereol · 2026-Jul 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The evolving role of neoadjuvant immunotherapy in resectable non-small cell lung cancer: a narrative review. PMID 41660484 · J Thorac Dis · 2026-Jan-31 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Sequential platinum and PARP Inhibition enhances PD1 immunotherapy efficacy in murine Brca2 mutated pancreatic cancer. PMID 41620448 · Sci Rep · 2026-Jan-31 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 3 Figure · 4 Panel · risk unclear
Combined Intraperitoneal and Systemic Chemotherapy for Peritoneal Metastases: Drug Delivery Concepts, Pharmacokinetics, and Clinical Applications: A Narrative Review. PMID 41754921 · Pharmaceutics · 2026-Jan-30 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Immunogenicity and Safety of the ExPEC9V Escherichia coli Vaccine Co-Administered with a High-Dose Influenza Vaccine in Older Adults: A Placebo-Controlled, Randomized, Phase 3 Study. PMID 41746067 · Vaccines (Basel) · 2026-Jan-30 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
PD-L1 subpopulations of metastatic urothelial carcinoma demonstrate heterogeneity to chemotherapy: an integrated analysis of digitized trial results. PMID 41615520 · Cancer Metastasis Rev · 2026-Jan-30 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A pragmatic trial with an optimized dose of rifampicin and moxifloxacin for the treatment of drug-susceptible pulmonary tuberculosis: a study protocol for open-label, randomized phase III trial (OptiRiMoxTB). PMID 41612490 · Trials · 2026-Jan-30 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial. PMID 41609025 · Haematologica · 2026-Jan-29 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Major Advances in Gynecologic Oncology in 2025: Systematic Review and Synthesis of Conference and Published Evidence. PMID 41751194 · Biomedicines · 2026-Jan-28 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Design, development, and evaluation of a web-based consultation system for birth after cesarean: a mixed-method study protocol. PMID 41606529 · BMC Pregnancy Childbirth · 2026-Jan-28 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Study protocol of a pilot randomised controlled trial examining massed culturally adapted Problem Management Plus (PM +) in South Africa. PMID 41593712 · Pilot Feasibility Stud · 2026-Jan-27 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A phase 2 study of orally administered live biotherapeutic salmonella-IL2 with FOLFIRINOX for stage IV pancreatic cancer. PMID 41591505 · Cancer Immunol Immunother · 2026-Jan-27 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Drug re-purposing to improve outcomes in the management of prostate cancer - aims, outcome measures and design of current phase III trials. PMID 41580831 · BMC Pharmacol Toxicol · 2026-Jan-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Evaluating the use of hierarchical composite endpoints in pediatric cancer supportive care clinical trials: Illustrative examples from two multi-center phase-III randomized clinical trials. PMID 41659071 · medRxiv · 2026-Jan-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -